The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva Pharmaceutical.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most…
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most…
Goldman Sachs has muted any upside view by downgrading Gilead Sciences to Sell and lowering its price target.
Jon C. Ogg The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia, Gilead Sciences, Goodyear, Philip Morris, Target and Zscaler.
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy,…
Here are 13 dirt cheap value stocks that are valued at less than 10 times earnings and that also pay steady dividends deemed to be safe as of mid-2019.
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
These five top stocks to Buy have solid upside potential, and some of them appear to have put some past issues that burdened share price behind.
It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes to Gilead…
Jon C. Ogg The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
